The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group
Abstract
Purpose: To evaluate frequency, biologic features, and clinical relevance of RUNX1 mutations in acute myeloid leukemia (AML). Patients and Methods: Diagnostic samples from 945 patients (age 18 to 60 years) were analyzed for RUNX1 mutations. In a subset of cases (n = 269), microarray gene expression analysis was performed. Results: Fifty-nine RUNX1 mutations were identified in 53 (5.6%) of 945 cases, predominantly in exons 3 (n = 11), 4 (n = 10), and 8 (n = 23). RUNX1 mutations clustered in the intermediate-risk cytogenetic group (46 of 640, 7.2%; cytogenetically normal, 34 of 538, 6.3%), whereas they were less frequent in adverse-risk cytogenetics (five of 109, 4.6%) and absent in core-binding-factor AML (0 of 77) and acute promyelocytic leukemia (0 of 61). RUNX1 mutations were associated with MLL-partial tandem duplications (P = .0007) and IDH1/IDH2 mutations (P = .03), inversely correlated with NPM1 (P < .0001), and in trend with CEBPA (P = .10) mutations. RUNX1 mutations were characterized by a distinct gene expression pattern; this RUNX1 mutation-derived signature was not exclusive for the mutation, but also included mostly adverse-risk AML [eg, 7q-, -7, inv(3), or t(3;3)]. RUNX1 mutations predicted for resistance to chemotherapy (rates of refractory disease 30% and 19%, P = .047, for RUNX1-mutated and wild-type patients, respectively), as well as inferior event-free survival (EFS; P < .0001), relapse-free survival (RFS, P = .022), and overall survival (P = .051). In multivariable analysis, RUNX1 mutations were an independent prognostic marker for shorter EFS (P = .007). Explorative subgroup analysis revealed that allogeneic hematopoietic stem-cell transplantation had a favorable impact on RFS in RUNX1-mutated patients (P < .0001). Conclusion: AML with RUNX1 mutations are characterized by distinct genetic properties and are associated with resistance to therapy and inferior outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Self-citationFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Self-citationPrognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Ko, M., Huang, Y., Jankowska, A. M., Pape, U. J., Tahiliani, M., Bandukwala, H. S., An, J., Lamperti, E. D., Koh, K. P., Ganetzky, R., et al. (2010) · Nature · doi:10.1038/nature09586 · Cited by 1,213
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139
Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., et al. (1999) · Nature Genetics · doi:10.1038/13793 · Cited by 1,100
Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia
Bullinger, L., Döhner, K., Bair, E., Fröhling, S., Schlenk, R. F., Tibshirani, R., Döhner, H., & Pollack, J. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031046 · Cited by 993
Self-citationQuivoron, C., Couronné, L., Della Valle, V., Lopez, C. K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.003 · Cited by 924
Paschka, P., Schlenk, R. F., Gaidzik, V. I., Habdank, M., Krönke, J., Bullinger, L., Späth, D., Kayser, S., Zucknick, M., Götze, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3762 · Cited by 801
Self-citationMarcucci, G., Maharry, K., Wu, Y.-Z., Radmacher, M. D., Mrózek, K., Margeson, D., Holland, K. B., Whitman, S. P., Becker, H., Schwind, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3730 · Cited by 763
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210039 · Cited by 727
Acquired mutations in TET2 are common in myelodysplastic syndromes
Langemeijer, S. M. C., Kuiper, R. P., Berends, M., Knops, R., Aslanyan, M. G., Massop, M., Stevens-Linders, E., van Hoogen, P., van Kessel, A. G., Raymakers, R. A. P., et al. (2009) · Nature Genetics · doi:10.1038/ng.391 · Cited by 680
Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
Marcucci, G., Haferlach, T., & Döhner, H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2554 · Cited by 570
Self-citationMrózek, K., Marcucci, G., Paschka, P., Whitman, S. P., & Bloomfield, C. D. (2007) · Blood · doi:10.1182/blood-2006-06-001149 · Cited by 552
Self-citationTefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.69 · Cited by 534
Expanding chemical biology of 2-oxoglutarate oxygenases
Loenarz, C., & Schofield, C. J. (2008) · Nature Chemical Biology · doi:10.1038/nchembio0308-152 · Cited by 497
Tefferi, A., Pardanani, A., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Gangat, N., Finke, C. M., Schwager, S., Mullally, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.47 · Cited by 425
Osato, M., Asou, N., Abdalla, E., Hoshino, K., Yamasaki, H., Okubo, T., Suzushima, H., Takatsuki, K., Kanno, T., Shigesada, K., et al. (1999) · Blood · doi:10.1182/blood.v93.6.1817.406k36_1817_1824 · Cited by 397
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia
Kharas, M. G., Lengner, C. J., Al-Shahrour, F., Bullinger, L., Ball, B., Zaidi, S., Morgan, K., Tam, W., Paktinat, M., Okabe, R., et al. (2010) · Nature Medicine · doi:10.1038/nm.2187 · Cited by 379
Self-citationNFAT proteins: emerging roles in cancer progression
Mancini, M., & Toker, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2735 · Cited by 371
Tang, J.-L., Hou, H.-A., Chen, C.-Y., Liu, C.-Y., Chou, W.-C., Tseng, M.-H., Huang, C.-F., Lee, F.-Y., Liu, M.-C., Yao, M., et al. (2009) · Blood · doi:10.1182/blood-2009-05-223784 · Cited by 344
Jankowska, A. M., Szpurka, H., Tiu, R. V., Makishima, H., Afable, M., Huh, J., O'Keefe, C. L., Ganetzky, R., McDevitt, M. A., & Maciejewski, J. P. (2009) · Blood · doi:10.1182/blood-2009-02-205690 · Cited by 331
Oncogenic potential of the RUNX gene family: ‘Overview’
Ito, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1207755 · Cited by 316
Leukaemogenesis: more than mutant genes
Chen, J., Odenike, O., & Rowley, J. D. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2765 · Cited by 311
Harada, H., Harada, Y., Niimi, H., Kyo, T., Kimura, A., & Inaba, T. (2004) · Blood · doi:10.1182/blood-2003-09-3074 · Cited by 281
Metzeler, K. H., Maharry, K., Radmacher, M. D., Mrózek, K., Margeson, D., Becker, H., Curfman, J., Holland, K. B., Schwind, S., Whitman, S. P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7742 · Cited by 280
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
Kosmider, O., Gelsi-Boyer, V., Cheok, M., Grabar, S., Della-Valle, V., Picard, F., Viguié, F., Quesnel, B., Beyne-Rauzy, O., Solary, E., et al. (2009) · Blood · doi:10.1182/blood-2009-04-215814 · Cited by 276
Tefferi, A., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Patnaik, M. M., Hanson, C. A., Pardanani, A., Gilliland, D. G., & Levine, R. L. (2009) · Leukemia · doi:10.1038/leu.2009.59 · Cited by 268
Preudhomme, C., Warot-Loze, D., Roumier, C., Grardel-Duflos, N., Garand, R., Lai, J. L., Dastugue, N., Macintyre, E., Denis, C., Bauters, F., et al. (2000) · Blood · doi:10.1182/blood.v96.8.2862 · Cited by 263
Owen, C. J., Toze, C. L., Koochin, A., Forrest, D. L., Smith, C. A., Stevens, J. M., Jackson, S. C., Poon, M.-C., Sinclair, G. D., Leber, B., et al. (2008) · Blood · doi:10.1182/blood-2008-05-156745 · Cited by 242
Wagner, K., Damm, F., Göhring, G., Görlich, K., Heuser, M., Schäfer, I., Ottmann, O., Lübbert, M., Heit, W., Kanz, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6899 · Cited by 241
Self-citationSchlenk, R. F., Döhner, K., Mack, S., Stoppel, M., Király, F., Götze, K., Hartmann, F., Horst, H. A., Koller, E., Petzer, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6856 · Cited by 228
Self-citationChou, W.-C., Huang, H.-H., Hou, H.-A., Chen, C.-Y., Tang, J.-L., Yao, M., Tsay, W., Ko, B.-S., Wu, S.-J., Huang, S.-Y., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283291 · Cited by 227
Gaidzik, V. I., Schlenk, R. F., Moschny, S., Becker, A., Bullinger, L., Corbacioglu, A., Krauter, J., Schlegelberger, B., Ganser, A., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-10-183392 · Cited by 190
Self-citationPrognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
Thol, F., Damm, F., Wagner, K., Göhring, G., Schlegelberger, B., Hoelzer, D., Lübbert, M., Heit, W., Kanz, L., Schlimok, G., et al. (2010) · Blood · doi:10.1182/blood-2010-03-272146 · Cited by 186
Self-citationTanner, S. M., Austin, J. L., Leone, G. W., Rush, L. J., Plass, C., Heinonen, K., Mrózek, K., Sill, H., Knuutila, S., Kolitz, J. E., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241525498 · Cited by 172
Rocquain, J., Carbuccia, N., Trouplin, V., Raynaud, S., Murati, A., Nezri, M., Tadrist, Z., Olschwang, S., Vey, N., Birnbaum, D., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-401 · Cited by 171
Molecular characterization of acute myeloid leukemia
Dohner, K., & Dohner, H. (2008) · Haematologica · doi:10.3324/haematol.13345 · Cited by 167
Censoring distributions as a measure of follow‐up in survival analysis
Korn, E. L. (1986) · Statistics in Medicine · doi:10.1002/sim.4780050306 · Cited by 166
Nibourel, O., Kosmider, O., Cheok, M. H.-C., Boissel, N., Renneville, A., Philippe, N., Dombret, H., Dreyfus, F., Quesnel, B., Geffroy, S., et al. (2010) · Blood · doi:10.1182/blood-2009-07-234484 · Cited by 140
Dicker, F., Haferlach, C., Kern, W., Haferlach, T., & Schnittger, S. (2007) · Blood · doi:10.1182/blood-2007-02-072595 · Cited by 127
Prognostic Implications of Gene Mutations in Acute Myeloid Leukemia With Normal Cytogenetics
Gaidzik, V. I., & Döhner, K. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.005 · Cited by 110
Self-citationTET Genes: new players in DNA demethylation and important determinants for stemness
Mohr, F., Döhner, K., Buske, C., & Rawat, V. P. S. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.12.004 · Cited by 103
Self-citationAn FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML
Bullinger, L., Döhner, K., Kranz, R., Stirner, C., Fröhling, S., Scholl, C., Kim, Y. H., Schlenk, R. F., Tibshirani, R. J., Döhner, H., et al. (2008) · Blood · doi:10.1182/blood-2007-09-115055 · Cited by 99
Self-citationBurmeister, T., Meyer, C., Schwartz, S., Hofmann, J. P., Molkentin, M., Kowarz, E., Schneider, B., Raff, T., Reinhardt, R., Gökbuget, N., et al. (2009) · Blood · doi:10.1182/blood-2008-10-183483 · Cited by 97
Dunne, J., Cullmann, C., Ritter, M., Martinez-Soria, N., Drescher, B., Debernardi, S., Skoulakis, S., Hartmann, O., Krause, M., Krauter, J., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209638 · Cited by 94
Self-citationEpigenetic gene silencing by Runx proteins
Taniuchi, I., & Littman, D. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207671 · Cited by 68
Taketani, T., Taki, T., Takita, J., Tsuchida, M., Hanada, R., Hongo, T., Kaneko, T., Manabe, A., Ida, K., & Hayashi, Y. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10246 · Cited by 63
Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7
Langabeer, S. E., Gale, R. E., Rollinson, S. J., Morgan, G. J., & Linch, D. C. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10031 · Cited by 62
TET proteins in malignant hematopoiesis
Langemeijer, S. M. C., Aslanyan, M. G., & Jansen, J. H. (2009) · Cell Cycle · doi:10.4161/cc.8.24.10239 · Cited by 60
Matsuno, N., Osato, M., Yamashita, N., Yanagida, M., Nanri, T., Fukushima, T., Motoji, T., KUSUMOTO, S., Towatari, M., Suzuki, R., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403160 · Cited by 60
KIT mutations confer a distinct gene expression signature in core binding factor leukaemia
Lück, S. C., Russ, A. C., Du, J., Gaidzik, V. I., Schlenk, R. F., Pollack, J. R., Döhner, K., Döhner, H., & Bullinger, L. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08035.x · Cited by 48
Self-citationHigh-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia
Schlenk, R. F., Germing, U., Hartmann, F., Glasmacher, A. G., Fischer, J.-T., y Fuentes, F. D. V., Götze, K. S. S., Pralle, H., Nerl, C., Salwender, H. J., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403766 · Cited by 45
Self-citationSchaich, M. A., Illmer, T., Seitz, G., Mohr, B., Schäkel, U., Beck, J. F., & Ehninger, G. (2001) · PubMed · Cited by 35
Gene Expression With Prognostic Implications in Cytogenetically Normal Acute Myeloid Leukemia
Baldus, C. D., & Bullinger, L. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.006 · Cited by 33
Self-citationAccordi, B., Pillozzi, S., Dell'Orto, M. C., Cazzaniga, G., Arcangeli, A., Kronnie, G. T., & Basso, G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706314200 · Cited by 22
Cited by
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Self-citationDöhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,306
Self-citationThe genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596
Acute myeloid leukemia: current progress and future directions
Kantarjian, H., Kadia, T., DiNardo, C., Daver, N., Borthakur, G., Jabbour, E., Garcia-Manero, G., Konopleva, M., & Ravandi, F. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00425-3 · Cited by 776
Metadata
- Authors
- Gaidzik, V. I., Bullinger, L., Schlenk, R. F., Zimmermann, A. S., Röck, J., Paschka, P., Corbacioglu, A., Krauter, J., Schlegelberger, B., Ganser, A., Späth, D., Kündgen, A., Schmidt-Wolf, I. G. H., Götze, K., Nachbaur, D., Pfreundschuh, M., Horst, H. A., Döhner, H., & Döhner, K.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-04-01
- Volume
- 29
- Issue
- 10
- Pages
- 1364-1372
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2108718836
- Cited by
- 456
- References
- 72
- FWCI
- 23.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.